0

CMHC PULSE

Cardio Metabolic Health Congress – Official Blog

Empagliflozin FDA Approved for Prevention of Cardiovascular Death

In an unprecedented move, the US FDA approved the SGLT-2 inhibitor empagliflozin for the prevention of cardiovascular death in patients with type 2 diabetes and coexisting cardiovascular disease (CVD).

Empagliflozin was first approved in 2014 for the treatment of type 2 diabetes and later demonstrated cardiovascular risk reduction in the EMPA-REG trial. Specifically, treatment with empagliflozin significantly reduced the risk of myocardial infarction, stroke, and CV death, as well as death from any cause and hospitalization for heart failure, in more than 7000 adults with type 2 diabetes at high CV risk. Read more

Linking Fiber Facts & Heart Health

Several studies have demonstrated that the consumption of fiber has significantly lowered levels of cholesterol, reduces the risk of stroke and diabetes, helps with weight loss, and can ultimately prevent cardiovascular disease.

Fiber comes in two forms: soluble and insoluble, though most fiber-rich foods contain both types. While most people generally associate fiber with a healthy digestive system and track, research has shown that its benefits for heart health are significant. Read more